Samuel F Colin Net Worth

What's Samuel Colin's mailing address?

Samuel's mailing address filed with the SEC is C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW, CA, 94041.

Insiders trading at VIVUS

Over the last 21 years, insiders at VIVUS have traded over 6,261,269$ worth of VIVUS stock and bought 5,180,746 units worth 13,074,554$ . The most active insiders traders include Tide Capital, Llc North Tid...、Alexander J Denner、Ernest Mario. On average, VIVUS executives and independent directors trade stock every 39 days with the average trade being worth of 35,394$. The most recent stock trade was executed by John P. Amos on 1 March 2019, trading 11,000 units of VVUS stock currently worth 53,350$.

What does VIVUS do?

VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.

VIVUS executives and stock owners

VIVUS executives and other stock owners filed with the SEC include:

• John Amos,
  Chief Executive Officer, Director
• John Slebir,
  Senior Vice President - Business Development, General Counsel, Secretary
• Santosh Varghese,
  Senior Vice President, Chief Medical Officer
• Mark Oki,
  Chief Financial Officer, Senior Vice President, Chief Accounting Officer
• Thomas King,
  Independent Director
• David Norton,
  Independent Chairman of the Board
• Jill Frizzley,
  Independent Director
• Herman Rosenman,
  Independent Director
• Jorge Plutzky,
  Independent Director
• Edward Kangas,
  Independent Director
• Karen Ferrell,
  Independent Director
• Allan Shaw,
  Director
• Herm Rosenman,
  Director
• Eric W Roberts,
  Director
• Tide Capital, Llc North Tid...,
  
• Seth H. Z. Fischer,
  Chief Executive Officer
• Mayu Sris,
  Director
• Kenneth Suh,
  President
• Wesley Day,
  Vice President, Clinical
• Michael /Ny/ Miller,
  Chief Commercial Officer
• Wang Changjin,
  VP, Business Development
• Virgil A Place,
  Chairman & CSO
• Graham Strachan,
  Director
• Samuel F Colin,
  Director
• Ernest Mario,
  Director
• Anthony P. Zook,
  Chief Executive Officer
• John W Dietrich,
  Vice President, R & D
• Terry Nida,
  VP, Worldwide Marketing/
• Svai S Sanford,
  Interim CFO
• Mario M Rosati,
  Director
• Alexander J Denner,
  Director
• Jon C Biro,
  10% owner
• J Martin Carroll,
  Director
• Robert N Wilson,
  Director
• Alexander J Sarissa Capital...,
  
• M. Scott Oehrlein,
  Chief Operations Officer
• Timothy E Morris,
  VP, Finance and CFO
• Leland F Wilson,
  President & CEO
• Linda M Dairiki Shortliffe,
  Director
• Charles J Casamento,
  Director
• Lee Perry,
  Vice President & Chief
• Jacob Pieter Kastelein Joha...,
  Director
• Michael J Astrue,
  Director
• Mark B Logan,
  Director
• Michael Patrick Miller,
  SVP, Chief Commercial Officer
• Guy P Marsh,
  VP, Operations & General Mgr.
• Neil Gesundheit,
  VP, Chief Medical Officer
• Larry J Strauss,
  Vice President, Finance & CFO
• James R Nickel,
  Vice President, Clinical
• Peter Y Tam,
  VP, Business Planning
• Carol Zoltowski,
  Vice President, Regulatory
• Lori Forrest,
  VP, Operations & General Mgr.